FOXO4-10mg

The FOXO4-DRI represents a significant advancement in the field of senolytic agents, compounds that selectively induce the death of senescent cells. This synthetic peptide is intricately designed, with a molecular structure derived from the FOXO4 transcription factor and composed of a D-amino acid sequence. This configuration not only enhances its stability but also improves its bioavailability.

At the heart of FOXO4-DRI’s mechanism of action is its ability to disrupt the interaction between the FOXO4 protein and p53, a key player in cell cycle regulation and apoptosis. In senescent cells, which are cells that have ceased to divide and accumulate in tissues, this interaction helps them resist apoptosis.

By intervening in this process, FOXO4-DRI specifically targets these senescent cells, triggering their death and thereby mitigating their contribution to aging and age-related diseases. Senescent cells are known for their pro-inflammatory secretory phenotype, termed the Senescence-Associated Secretory Phenotype (SASP), which FOXO4-DRI effectively reduces, improving tissue function.

For Research Use Only

Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells

Expression and clinical significance of FOX04 in colorectal cancer